Mifamurtide CAS:83461-56-7

Mifamurtide is primarily used to treat osteosarcoma, the most common type of bone tumor in children and adolescents. As an immune enhancer, it enhances the host's immune response to tumor cells by activating the function of macrophages and T cells, thereby inhibiting tumor growth and spread. Mifamurtide enhances the host anti-tumor immune response by promoting the activation and proliferation of natural killer cells. This drug is often used in combination with other treatments, such as surgery and chemotherapy, especially when used before and after surgery to reduce the risk of tumor recurrence and metastasis. Clinical studies have shown that Mifamurtide can significantly improve survival and treatment outcomes in patients with osteosarcoma. It is not only effective in newly treated patients, but also has shown some efficacy in patients with relapsed or refractory osteosarcoma. Although its primary application is in osteosarcoma, there are also studies exploring its potential in the treatment of other types of cancer, especially those tumor types that rely on an immune response. Overall, Mifamurtide, as a targeted immunotherapy agent, offers an effective and relatively safe treatment option for patients with osteosarcoma, offering hope for improving patient survival and quality of life.